Biotech Market Profits from Biotech: Mid-Cap Firms Increase Revenues to 26.5 Billion
With combined total revenues of US $ 26.5 billion in 2014, mid mid-cap biotech reaches a 21.9 % growth. Especially two companies are the key driver behind this successtora, recent figure show.
The combined total revenues for the peer group of 35 mid-cap biotech companies increased from US $ 24.8 billion in 2013 to US $ 26.5 billion in 2014, representing a Compound Annual Growth Rate (CAGR) of 21.9 %, according to research and consulting firm Global Data. The company’s latest report states that this growth was marginally slower than during the previous five years, as total revenues for this peer group expanded at a CAGR of 25.2% between 2009 and 2013.
Adam Dion, MS, Global Data’s Healthcare Industry Analyst, says the rise in biotech peer group total revenue over the past year was driven by Regeneron and Alexion, both of which posted sales of more than US $ 2 billion in 2014.
Dion explains: “Regeneron’s sales grew by 34% in 2014, as the company continued its commercialization of Eylea (afilibercept) to markets outside the US, including for the treatment of macular edema secondary to central retinal vein occlusion in both the EU and Japan.
Sales from Orphan Drugs Rise
“Alexion saw sales from its orphan drug Soliris (eculizumab) increase from US $ 1.6 billion in 2013 to US $ 2.2 billion in 2014. Alexion reported a higher volume of unit shipments and better-than-expected demand for Soliris across all geographic regions, especially in the EU, thanks to a reimbursement agreement with the French government.”
The analyst adds that Pharmacyclics, which was acquired by pharmaceutical giant AbbVie last month, was the peer group revenue growth leader in 2014. Its sales shot up by 180% in 2014 to $729 million, representing an absolute dollar increase of nearly $470 million.
Cancer Treatments Move the Market
Global Data attributes this surge to Pharmacyclics recognizing nearly US $ 493 million in new product revenue from sales of Imbruvica (ibrutinib), the company’s first-in-class BTK inhibitor approved to treat blood cancer patients with chronic lymphocytic leukemia and mantle cell lymphoma.
By contrast, some companies experienced sales decreases, most notably Vertex, which saw revenues decline by 52.1 %, from US $ 1.2 billion in 2013 to US $ 580.4 million in 2014.
Dion comments: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex’s hepatitis C virus protease inhibitor, which fell by US $ 442.3 million compared with 2013, primarily as a result of increased competition from Gilead’s Sovaldi (sofosbuvir) and Janssen’s Olysio (simeprevir).”